Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ahmet Soysal. (2015) Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infection and Drug Resistance 8, pages 321-331.
Read now
Read now
Hasan Tezer, Fuat Emre Canpolat & Uğur Dilmen. (2012) Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis. Expert Opinion on Pharmacotherapy 13:2, pages 193-205.
Read now
Read now
Maged Muhammed, Herman Carneiro, Jeffrey Coleman & Eleftherios Mylonakis. (2011) The challenge of managing fusariosis. Virulence 2:2, pages 91-96.
Read now
Read now
Stefan Langner, Philipp B Staber & Peter Neumeister. (2008) Posaconazole in the management of refractory invasive fungal infections. Therapeutics and Clinical Risk Management 4:4, pages 747-758.
Read now
Read now
Mario Cruciani & Giovanni Serpelloni. (2008) Management of Candida infections in the adult intensive care unit. Expert Opinion on Pharmacotherapy 9:2, pages 175-191.
Read now
Read now
Articles from other publishers (29)
Ali Haider, Muhammad Ikram & Asma RafiqAli Haider, Muhammad Ikram & Asma Rafiq. 2023. Green Nanomaterials as Potential Antimicrobials. Green Nanomaterials as Potential Antimicrobials
125
139
.
Michail Lykouras, Malvina Orkoula & Christos Kontoyannis. (2022) Formation and Characterisation of Posaconazole Hydrate Form. Pharmaceuticals 16:1, pages 65.
Crossref
Crossref
Alfredo G. Puing, Antoine Couture‐Cossette, Aileen X. Wang, Corinna C. Zygourakis, Xingxing Cheng, Bryan A. Stevens, Niaz Banaei, Roberto A. Novoa, Dora Y. Ho & Aruna K. Subramanian. (2020) Simultaneous coccidioidomycosis and phaeohyphomycosis in a kidney transplant recipient: A case report and literature review. Transplant Infectious Disease 22:6.
Crossref
Crossref
Lindice Mitie Nisimura, Patrícia Mello Ferrão, Alanderson da Rocha Nogueira, Mariana Caldas Waghabi, Marcelo Meuser-Batista, Otacílio C. Moreira, Julio A. Urbina & Luciana Ribeiro Garzoni. (2020) Effect of Posaconazole in an in vitro model of cardiac fibrosis induced by Trypanosoma cruzi. Molecular and Biochemical Parasitology 238, pages 111283.
Crossref
Crossref
Alexander V. Veselov. (2020) The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies. Clinical Microbiology and Antimicrobial Chemotherapy 22:2, pages 96-117.
Crossref
Crossref
Athanasios Tragiannidis, Heidrun Herbrüggen, Martina Ahlmann, Eleni Vasileiou, Silke Gastine, Heike Thorer, Birgit Fröhlich, Carsten Müller & Andreas H Groll. (2019) Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. Journal of Antimicrobial Chemotherapy 74:12, pages 3573-3578.
Crossref
Crossref
Arjuna Nishantha Bandara Ellepola, Ranil Samantha Dassanayake & Ziauddin Khan. (2019) In vitro Post-Antifungal Effect of Posaconazole and Its Impact on Adhesion-Related Traits and Hemolysin Production of Oral <b><i>Candida dubliniensis</i></b> Isolates. Medical Principles and Practice 28:6, pages 552-558.
Crossref
Crossref
Wilton H. Kawaguchi, Leticia Bonancio Cerqueira, Mariana Millan Fachi, Michel L. Campos, Iara J. Messias Reason & Roberto Pontarolo. 2018. Chagas Disease - Basic Investigations and Challenges. Chagas Disease - Basic Investigations and Challenges.
Robson Xavier Faria, Daniel Tadeu Gomes Gonzaga, Paulo Anastácio Furtado Pacheco, André Luis Almeida Souza, Vitor Francisco Ferreira & Fernando de Carvalho da Silva. (2018) Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells. Journal of Bioenergetics and Biomembranes 50:2, pages 81-91.
Crossref
Crossref
Sevtap Arikan-Akdagli & John H. Rex. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
1367
1387
.
Clarence S. Yah & Geoffrey S. Simate. (2015) Nanoparticles as potential new generation broad spectrum antimicrobial agents. DARU Journal of Pharmaceutical Sciences 23:1.
Crossref
Crossref
Limin Yao, Zhe Wan, Ruoyu Li & Jin Yu. (2015)
In Vitro
Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species
. Antimicrobial Agents and Chemotherapy 59:8, pages 5040-5043.
Crossref
Crossref
Kate McKeage. (2015) Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections. Drugs 75:4, pages 397-406.
Crossref
Crossref
Israel Molina, Jordi Gómez i Prat, Fernando Salvador, Begoña Treviño, Elena Sulleiro, Núria Serre, Diana Pou, Sílvia Roure, Juan Cabezos, Lluís Valerio, Albert Blanco-Grau, Adrián Sánchez-Montalvá, Xavier Vidal & Albert Pahissa. (2014) Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease. New England Journal of Medicine 370:20, pages 1899-1908.
Crossref
Crossref
Jane Pak, Veronica T. Tucci, Mitsuya Katayama, Albert L. Vincent, Ramon L. Sandin & John N. Greene. (2014) Treatment of Disseminated Rhizomucor With a Combination of Ambisome and Posaconazole. Infectious Diseases in Clinical Practice 22:2, pages 65-67.
Crossref
Crossref
David A. Stevens. (2013) Reflections on the Approach to Treatment of a Mycologic Disaster. Antimicrobial Agents and Chemotherapy 57:4, pages 1567-1572.
Crossref
Crossref
Kevin Woodward & Kevin WoodwardK. N. Woodward. 2012. Toxicological Effects of Veterinary Medicinal Products in Humans. Toxicological Effects of Veterinary Medicinal Products in Humans
71
94
.
Malcolm D. Richardson & David W. Warnock. 2012. Fungal Infection. Fungal Infection
32
90
.
Herman Anthony Carneiro, Anastasios Mavrakis & Eleftherios Mylonakis. (2011) Candida Peritonitis: An Update on the Latest Research and Treatments. World Journal of Surgery 35:12, pages 2650-2659.
Crossref
Crossref
Shingo Yano, Jiro Minami, Kaichi Nishiwaki, Takaki Shimada, Nobuaki Dobashi, Yuichi Yahagi, Yutaka Takei, Shinobu Takahara, Yoji Ogasawara, Katsuki Sugiyama, Yuko Yamaguchi, Takeshi Saito, Kinuyo Kasama, Hiroki Yokoyama, Tomohito Machishima, Atsushi Katsube, Noriko Usui & Keisuke Aiba. (2011) Rapid progression and unusual premortal diagnosis of mucormycosis in patients with hematologic malignancies: analysis of eight patients. International Journal of Hematology 93:3, pages 344-350.
Crossref
Crossref
Herman A. Carneiro, Jeffrey J. Coleman, Alejandro Restrepo & Eleftherios Mylonakis. (2011) Fusarium Infection in Lung Transplant Patients. Medicine 90:1, pages 69-80.
Crossref
Crossref
Elizabeth Dodds‐Ashley. (2012) Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:8, pages 842-854.
Crossref
Crossref
David W. Warnock. 2010. Antibiotic and Chemotherapy. Antibiotic and Chemotherapy
366
382
.
G.L. Petrikkos. (2009) Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clinical Microbiology and Infection 15, pages 87-92.
Crossref
Crossref
E. Roilides, T.E. Zaoutis & T.J. Walsh. (2009) Invasive zygomycosis in neonates and children. Clinical Microbiology and Infection 15, pages 50-54.
Crossref
Crossref
Arnold L Demain & Sergio Sanchez. (2009) Microbial drug discovery: 80 years of progress. The Journal of Antibiotics 62:1, pages 5-16.
Crossref
Crossref
Sevtap Arikan & John H. Rex. 2009. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
1171
1186
.
Erik J Rachwalski, Jeffrey T Wieczorkiewicz & Marc H Scheetz. (2008) Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. Annals of Pharmacotherapy 42:10, pages 1429-1438.
Crossref
Crossref
R. Fleck & H. Hof. (2008) Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values. Mycoses 51, pages 1-4.
Crossref
Crossref